



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 49/00	A1	(11) International Publication Number: WO 92/10213
		(43) International Publication Date: 25 June 1992 (25.06.92)
(21) International Application Number: PCT/US91/09222	(72) Inventors; and	
(22) International Filing Date: 6 December 1991 (06.12.91)	(75) Inventors/Applicants (for US only): YOUNG, Stuart, W. [US/US]; 45 Las Piedras Ct., Portola Valley, CA 94028 (US). BALKUS, Kenneth, J., Jr. [US/US]; 4168 Ballard Trail, The Colony, TX 75056 (US). SHERRY, A., Dean [US/US]; 6934 Spanky Branch, Dallas, TX 75248 (US).	
(30) Priority data: 624,106 7 December 1990 (07.12.90) US		
(60) Parent Application or Grant (63) Related by Continuation US 624,106 (CIP) Filed on 7 December 1990 (07.12.90)	(74) Agent: KITCHELL, Barbara, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).	
(71) Applicant (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).	(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.	
		<p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(54) Title: MOLECULAR SIEVE-ENCLOSED PARAMAGNETIC ION FOR DIAGNOSIS		
(57) Abstract		
<p>The invention relates to a method of using molecular sieve-enclosed paramagnetic ions as image brightening or image contrast agents. In particular, zeolite enclosed trivalent gadolinium is useful in MRI studies of the entire gastrointestinal tract, providing excellent images. Zeolite-enclosed gadolinium complexes may be conveniently administered in oral preparations without side effects of diarrhea. Other transition metal ions, including divalent manganese may be enclosed in any suitable molecular sieve which has ion exchange properties sufficient to exchange the selected metal. The exchanged paramagnetic metal ion may be a free ion within the zeolite framework or ligated with a chelator. Alternatively, a paramagnetic metal ion may be included as part of the molecular sieve framework.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU*	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

MOLECULAR SIEVE-ENCLOSED PARAMAGNETIC ION FOR DIAGNOSIS

5 The invention relates to contrast or imaging agents useful in vivo for studies and diagnosis of the gastrointestinal tract. The agents are molecular sieve materials enclosing a paramagnetic ion such as trivalent gadolinium. The loaded molecular sieves are particularly
10 suitable for oral administration and function well as magnetic resonance imaging contrast or image brightening agents in the upper gastrointestinal tract.

 The availability of sophisticated methods such as
15 MRI and CT has contributed to the increased use of imaging technology in therapy and diagnostic studies. Gastrointestinal tract imaging is a particular area of interest because currently used imaging agents generally
20 provide poor imaging, resulting in visualization of little more than gross blockages or anatomical abnormalities.

 Barium sulfate and paramagnetic iron oxide are agents traditionally used for gastrointestinal studies.
25 The latter material has become popular because of the paramagnetic properties of Fe_2O_3 , which is suited for MRI studies, but it has many disadvantages. These include black bowel, side effects of diarrhea and, from an important analytical standpoint, the presence of
30 artifacts arising from clumping. When paramagnetic iron concentrates, it may become ferromagnetic, drastically altering its imaging properties. Even when images are obtained, the signal is black, making it difficult to distinguish imaged from nonimaged areas.

35

 The development of imaging contrast agents, particularly for gastrointestinal tract studies has been

-2-

slow. Historically, the most popular agent has been superparamagnetic iron oxide for magnetic imaging, due to its nonbiodegradability. Although good contrast effects have been achieved in some MR studies in the small bowel, increasing occurrence of blurring and "metal" artifacts in the distal part of the bowel has been recorded (Lonnemark et al., 1989). In other studies with superparamagnetic iron oxide, good resolution of the head and tail of the pancreas, anterior margins of the kidneys and para-aortic region has been shown in human patients. However, there are undesirable side effects such as episodes of diarrhea in some patients (Hahn et al., 1990).

Magnetic imaging is particularly useful for the study and diagnosis of tumors or inflammatory abdominal diseases. Paramagnetic species represented by gadolinium seem to be potentially agents for these studies, the metal itself cannot be used in humans because of its toxic properties. Nevertheless, diethylenetriamine penta-acetic acid (DTPA) complexes of trivalent gadolinium have less toxicity than the uncomplexed salt and have been tested in human patients. Opacification of the gastrointestinal tract has been reported, but less than 60% of the magnetic resonance scans showed improved delineation of abdominal pathologies. Furthermore, nearly 40% of the patients reported diarrhea and meteorism (Claussen et al., 1989).

Encapsulation of solid paramagnetic complexes in sulfonated ion-exchange resins for use in abdominal imaging has been suggested. It has been speculated that such encapsulation in acid-stable materials would prevent significant demetallation which otherwise occurs in the stomach when image contrasting agents are orally administered for gastrointestinal tract imaging

-3-

(Braybrook and Hall, 1989).

Superparamagnetic iron oxide has been coated onto a polymer carrier matrix and evaluated as an oral contrast medium for MRI. Generally good images were obtained in the region of the small bowel, except the duodenum, but the useful concentration range appeared to be fairly narrow since some concentrations caused an artifact in the stomach after ingestion of the agent (Lonnemark et al., 1989).

There is clearly a need for orally effective, well-tolerated agents that can be used in humans for imaging studies. In particular, an MRI imaging agent applicable to gastrointestinal tract studies would be useful for visualizing the anatomy of the intestinal tract and particularly to differentiate normal and pathological states, such as tumors. An effective, orally deliverable paramagnetic imaging contrast agent devoid of the common side effects currently encountered with the presently used GI imaging agents would represent a significant improvement over the iron and gadolinium complexes described. These compounds have several problems, including toxicity and lack of good image quality. Even with reports of improved compositions such as carrier complexes and matrices, some areas of the intestine are inadequately visualized with these materials and side effects still exist. For example, although trivalent gadolinium is an excellent paramagnetic MRI contrast species, its toxicity limits use in humans to its DTPA complex, which itself may exhibit toxicity.

-4-

The present invention addresses one or more of the foregoing or other problems associated with use of presently available agents of choice in imaging studies, particularly in gastrointestinal imaging. A nontoxic zeolite molecular sieve carrier that preferentially binds paramagnetic metal ions within a lattice-like structure has been shown to have little toxicity and to exhibit excellent imaging properties. Furthermore, many of the problems associated with the use of superparamagnetic iron oxide are eliminated, including metal imaging and patient side effects such as diarrhea.

In one aspect of the invention, a zeolite-enclosed paramagnetic metal ion is utilized for contrast imaging in animals or humans. Effective, sharp imaging is possible because the paramagnetic ion remains relatively tightly held within the zeolite matrix, being preferentially bound compared with cations such as sodium.

Preparations of paramagnetic metal ions enclosed in a zeolite molecular sieve are orally administrable and, because little leakage of potentially harmful metal ions occurs, nontoxic. Preferred paramagnetic species include trivalent gadolinium and divalent manganese with trivalent gadolinium enclosed in a faujasite group zeolite such as CaA or NaX to form CaGdA or NaGdX representing a most preferred embodiment.

Generally, the invention is an imaging method which involves administering a paramagnetic ion enclosed in zeolite. Most often the method will be used in humans but of course it could be used in animals, for example, in veterinary practice for diagnosis of gastrointestinal abnormalities. The amount of paramagnetic ion enclosed within the zeolite is enough to be effective as a

-5-

contrast or imaging brightening agent. A particularly useful feature of this invention is the brightness of the areas imaged with zeolite enclosed paramagnetic ions.

This contrasts with images obtained with

- 5 superparamagnetic iron oxide which develop as dark or deep gray areas. Brightly imaged areas are preferred over dark contrast for visualizing the anatomy of the area and for detecting pathologies because delineation is increased.

10

Zeolite-enclosed paramagnetic ions are particularly useful for imaging studies in human beings and have many advantages over superparamagnetic iron oxide.

Superparamagnetic iron tends to clump in the

- 15 gastrointestinal tract causing a conversion from paramagnetic to ferromagnetic properties. Additionally, superparamagnetic iron oxide administered in the quantities necessary for satisfactory imaging causes unpleasant side effects in human beings, including
- 20 diarrhea and meteorism. Such effects have not been observed with zeolite-enclosed trivalent gadolinium. The invention also overcomes the problems associated with toxicity of some of the paramagnetic metals considered most useful for MRI studies, for example trivalent
- 25 gadolinium. Toxicity of trivalent gadolinium has been reduced by combining it with dimethyltetraaminopentacetic acid (DTPA) to form a complex that exhibits less toxicity than the gadolinium salt. However, some studies with gadolinium DTPA indicate problems similar to those
- 30 encountered with super paramagnetic iron oxide, such as side effects of diarrhea and meteorism. In addition, the toxicity of the complex has not been fully determined. On the other hand, toxicity has not been observed with the use of zeolite-enclosed gadolinium. This may be due
- 35 to relatively tight binding of the metal ion within the zeolite molecular sieve.

-6-

Although the invention has been illustrated with trivalent gadolinium and divalent manganese, other ion species that ion exchange with a zeolite may be used. Examples include tetravalent vanadium, trivalent
5 vanadium, divalent copper, divalent nickel, trivalent chromium, divalent cobalt, divalent iron, trivalent iron and trivalent cobalt. Any of a number of salts of these species may be used to exchange a resident counterion in the zeolite, including chlorides, acetates, nitrates and
10 the like. These examples are not intended to be limiting; for example, other species capable of ion exchanging include members of the lanthanide series of elements and the rare earth elements.

15 There are numerous zeolites capable of entrapping paramagnetic ions and are therefore suitable for the practice of the invention. For example, the synthetic zeolites type A, type X, type Y or ZSM-5 type zeolite are particularly useful (Breck, 1984; Rankel and Valyocsik,
20 1983). Type X and type Y zeolites are faujasite (FAU) group zeolites, while type A zeolites are Linde type A zeolites (LTA). Many types of molecular sieves are available, differing in chemical composition, cavity diameter or natural occurrence, such as the mordenite
25 class of zeolites. Shapes of these substances are to some extent derived from the linkages of secondary building units forming the typical three-dimensional framework of the molecules. The shapes may then have an effect on ion exchange ability, selectivity in
30 restricting the passage of molecules based on size, and absorption properties.

Many molecular sieves that would not be considered zeolites also may be used to enclose metal ions useful
35 for imaging. Zeolites are a particular class of molecular sieves having an aluminosilicate framework

-7-

structure. Zeolite building blocks are Si^{4+} and Al^{3+} tetrahedra linked through common oxygen atoms extending in an infinite 3-dimensional network. When isomorphous atoms are substituted for aluminum or silicon (e.g.,
5 gallium, germanium or phosphorus), synthetic molecular sieves are created. Framework atoms may also be substituted with paramagnetic ions such as Mn^{2+} or Gd^{3+} . Molecular sieves, especially those that possess ion exchange properties, may be used analogously to zeolites.

10

Ion exchange properties of the zeolite are especially important in preferential binding of certain ions, particularly metal ions of the transition metal series. The amount of metal ion actually enclosed within
15 the zeolite will depend on the characteristics of the particular zeolite type used, as well as the presence of other positively charged ions. Thus, for example, if calcium zeolite type A is mixed with a gadolinium salt and allowed to equilibrate over a period of time, the
20 final exchange product will contain both positively charged gadolinium and calcium ions. However, these zeolites will preferentially exchange with the transition metal ions giving rise to greater concentrations of the transition metal ions than the ions from group 1 or group
25 2 elements when both types of ions are present. At any rate, the preferential binding of paramagnetic ions such as Gd^{3+} and Mn^{2+} is sufficient to give excellent MRI imaging properties when the zeolite-entrapped paramagnetic ion is used for imaging studies.

30

In another embodiment of the invention, complexed paramagnetic ions are enclosed within a zeolite matrix. Intrazeolite complexes may be prepared by at least two different methods, either by synthesizing the zeolite
35 around a complex or by diffusing a ligand into the zeolite where it then complexes with the metal ion.

Typical complexing agents include 8-hydroxyquinoline, dipiconilic acid and phthalic acid, but numerous other ligands may also be employed and may depend on the particular paramagnetic ion chosen for complexation. One
5 consideration in the selection of a ligand is the number of occupied sites on the metal ion. While 4-6 bonds will generally more tightly bind a metal ion, it may in some circumstances be desirable to employ fewer bonds, 2 for example, so that bulk water is more available to the
10 metal. Increased access to bulk water, as a general principle, enhances imaging intensities. Improved imaging may then be achieved with lower amounts of paramagnetic material.

15 A second consideration in the selection of a ligand is binding affinity.⁴ A larger number of ligands, e.g., 4-6, may be desirable to provide tighter binding to preclude loss of potentially toxic free metal ions. Multidentate ligands generally form more stable complexes
20 and are preferred. The ligands may be neutral or carry a charge where the complex would preferably have available a positive charge. Additionally, the ligand may have a paramagnetic functional group such as a nitroxide. The ligand radical combined with the metal ion may further
25 enhance imaging intensities.

Yet another embodiment of the invention is a paramagnetic metal ion enclosed in a molecular sieve both as a free metal ion, for example ion-exchanged into the
30 molecular sieve, and as a complexed metal ion. Such a composition has the advantage of the relatively high loading of a paramagnetic ion exchanged zeolite, combined with the advantages of having a paramagnetic ion held in the larger cavities of the zeolite, being therefore more
35 accessible to bulk water and enhancing image intensity. Complexation, especially chelation, localizes the active

-9-

species in larger pores with better access to water, yet reduces loss of the ion from the zeolite matrix. This may become a consideration if, for example, the zeolite were to partially digest after administration for

5 diagnostic purposes.

Zeolite enclosed paramagnetic ions are particularly useful for MRI studies of the gastrointestinal tract, especially since pharmaceutically acceptable preparations

10 of these materials can be administered enterically, for example, by nasogastric tube to either an animal or a human being. Oral administration is preferred for most applications involving studies or treatment of humans.

Detection of a molecular sieve enclosed paramagnetic ion after administration is most preferably performed by magnetic resonance imaging, although conventional radiographic imaging and computerized tomography (CT) may also be employed in a manner similar to techniques used

15 with BaSO₄ and gastrographin imaging. High Z (atomic weight) metals like gadolinium may also be detected by monochromatic x-ray sources, for example, K-edge imaging. Additionally, certain zeolite-enclosed metal complexes may be detected by fluorescence.

20

In a most preferred method of practice, the invention is used for gastrointestinal tract imaging. A pharmaceutically acceptable formulation including zeolite enclosed trivalent gadolinium is administered, preferably

25 orally, to a human or animal and detected by magnetic resonance imaging. The trivalent gadolinium may be enclosed within calcium type A zeolite, sodium type X zeolite or other suitable molecular sieve. In preferred practice, zeolite enclosed trivalent gadolinium is

30 prepared in a pharmaceutical carrier prior to administration.

35

-10-

The zeolite enclosed metal ion compounds of this invention may be combined with pharmaceutically acceptable formulating agents, dispersing agents and fillers. Powders, granules, capsules, coated tablets, 5 syrupy preparations and aqueous suspensions may be utilized for oral preparations. Formulating agents employed may be either solid or liquid, including but not limited to such solids as calcium phosphate, calcium carbonate, dextrose, sucrose, dextrin, sucrose ester, 10 starch, sorbitol, mannitol, crystalline cellulose, talc, kaolin, synthetic aluminum silicate, carboxymethyl cellulose, methylcellulose, cellulose acetate phthalate, alginates, polyvinyl pyrrolidone, polyvinyl alcohol, gum arabic, tragacanth gum, gelatin, bentonite, agar powder, 15 shellac, Tween 80, carrageenans and psyllium. Modified zeolite materials having residual charges or modifying groups might also be used which may be adsorbed to various carrier matrices such as clay. Examples of liquids suitable as suspending fluids include water, 20 isotonic salt solution, ethanol, propylene glycol, polyethylene glycol, glycerol, Hartman's solution and Ringer's solution. A preferred liquid for suspension is EZpaque supernatant which is readily obtained from EZpaque after removing BaSO_4 , either by centrifugation or 25 filtration.

Administration is most preferably oral because of better patient acceptance in that form but administration may also be intravascular, enteric, vaginal, anal or by 30 direct introduction into the gastrointestinal tract at any point such as by introduction through tubes accessing the alimentary canal. Flavor enhancers may be added to oral preparations, including taste masking substances such as sweeteners and citrus flavors. Other additives, 35 including color, preservatives, bulk or antifoam agents may also be included in the formulation. Examples of

-11-

non-oral use include retrograde pelvic studies and investigations to define vaginal contents. Intravascular administration is also expected to be effective. Particulates such as colloidal iron oxide have been
5 injected into the bloodstream without ill effect, indicating that stable molecular sieve particulates would likewise cause no problems as carriers.

The invention may also be used in conjunction with
10 magnetic resonance imaging of body surfaces. For example, artificial limbs must be custom fitted to leg, arm, hand or foot amputees. Present methods are time-consuming and rendered difficult because photographs show only skin surface while x-ray indicates only dense
15 material such as bone. MRI could show both bone and skin and therefore facilitate design of a prosthetic device which must be customized to the remaining member of the body. Zeolite-enclosed trivalent gadolinium would be ideal for this purpose. The crystalline material would
20 be powdered sufficiently to be conveniently applied to a skin surface, preferably as an aerosol which could be either a dry powder or a suspension in a suitable fluid, for example water or alcohol. The skin is preferably first treated with an agent that promotes adherence of
25 the powder to the surface, for example, tincture of benzoin. Other applications envisioned are imaging of the foot, useful in customizing footwear for abnormal or injured feet. Surface imaging could also be used in connection with inanimate surfaces, for example some
30 metal surfaces. In some cases, especially where high resolution is desired, uniform application would be important so that surface roughness reflected the surface examined rather than an artifact of uneven application.

35 Zeolites having appropriate crystal dimensions may also be used as intravascular MRI contrast agents. While

-12-

oral preparations may be preferred by patients, direct injection into the bloodstream may provide advantages such as speed or visualization of constricted areas.

- 5 The zeolite enclosed ionic species of this invention will typically be formulated as suspensions or dispersions, preferably in EZ dispersant (available from E-ZM Company) or used as the supernatant from pharmacy-purchased suspensions of BaSO₄ under the trade name of
- 10 EZpaque) at a low weight to volume ratio. For oral administration this is preferably approximately 1%. Higher concentrations of the zeolite composition may be prepared as suspensions; however, for MR imaging purposes, image intensity decreases markedly above weight
- 15 ratios of 1%. The 1% suspensions in EZpaque supernatant appear to be stable indefinitely.

- A marked advantage of calcium gadolinium enclosed in type A zeolite is the relatively low concentration that
- 20 may be employed in a dispersing medium. For example, a one percent concentration of calcium gadolinium type A zeolite administered orally is effective in producing excellent images for MRI studies, although higher weight
- 25 percent concentrations may be utilized in accordance with the form of the preparation. In contrast, when barium sulfate is used in the same dispersing medium, concentrations of up to 40-50% by weight are required and precipitation is often a problem.

- 30 A most preferred paramagnetic ion useful for GI studies of this sort is trivalent gadolinium, however, other metal ions as listed above can be used. Excellent results have also been obtained using zeolite enclosed
- 35 divalent manganese.

It will be appreciated by those of skill in the art

-13-

that there will always be present within the zeolite not only the paramagnetic ion, complexed or free, which is used for the imaging, but also a second ion with which the paramagnetic ion was exchanged. The type of second ion will depend on the zeolite compound used in the preparation. For example, calcium zeolite, calcium type A zeolite, sodium zeolite or other salts formed from first and second group elements may be used. Alternatively, the parent zeolite could be exchanged with protons, alkali or alkaline earth metal ions, transition or rare earth metal ions prior or subsequent to entrapment of a paramagnetic ion. It should be further understood that a molecular sieve enclosing a paramagnetic ion may contain other ligands such as hydroxyl ion, chloride ion or water depending on the method of preparation. Any or all of these species may affect the properties of the enclosed ions. The presence of any one or a number of these may alter or attenuate the pharmacological effects of the zeolite enclosed paramagnetic ion.

Figure 1 is an MRI scan of the gastrointestinal tract of a rabbit taken after two administrations by NG tube of a 1% suspension of CaGdA at 12 hr and 4 hr before MRI scanning. Panel 1A illustrates the effect of the presence of CaGdA in the stomach. Panel 1B indicates delineation of the jejunum region of the intestine in the presence of CaGdA.

Figure 2 is an MRI scan of the gastrointestinal tract of a dog taken after administration by NG tube of a 1 % suspension of CaGdA. Panels A and B are scans taken 1 hr after administration. Panels C and D are scans taken 3 hr after administration.

The present invention relates particularly to

-14-

pharmaceutical compositions that include zeolite-enclosed paramagnetic ions and the utility of these species as contrast and image brightening agents. Suitable paramagnetic ions may be enclosed in a wide range of zeolites, either as a "free" ion within the zeolite cage or complexed with an appropriate complexing agent. By free ion is meant a charged species lacking ligands, but not necessarily precluding charge-charge interactions with other species. Such interactions may be in the form of counterion interactions within the cages of the enclosing zeolite, or, as compounds forming the zeolite framework, for example replacement of the metal portion of the aluminate.

Methods of preparation of zeolite enclosed metal ions are well-known in the art, and are generally based on the ion exchange properties of zeolites. Thus a paramagnetic ion such as gadolinium may be exchanged into many types of zeolites, including most of the faujasite group of zeolites, or even molecular sieves with ion-exchange properties.

In addition to zeolite-enclosed "free" metal ions, it has been discovered that useful imaging compositions may be obtained from zeolite-enclosed metal ion chelate complexes. Examples are provided showing that metal ion chelates may be formed *in situ*, that is, after the ion is enclosed within the zeolite, or, metal ion complexes may be enclosed by synthesizing the zeolite around a metal ion chelate.

Sodium type A and type X zeolites readily form around gadolinium(III) complexes of 8-hydroxyquinoline, dipiconilic acid and phthalic acid. Other suitable ligands may include salicylamide, salicylic acid, anthranilic acid, bipyridine, terpyridine,

-15-

phenanthroline, ethylenediamine,
bis(salicylaldehyde)ethylenediamine, ethylenediamine
diacetic acid or the like. Chelated paramagnetic
species, as a general rule, are larger than the free ion
5 and therefore must be located in the larger spaces within
the zeolite structure. Consequently, the paramagnetic
ion is more accessible to water than ions located in
smaller spaces. At comparable loadings of paramagnetic
ion, intensities are higher for chelated ions compared
10 with free ion counterparts within the zeolite.

Intensities measured with zeolite-enclosed chelated
paramagnetic ions indicate that complexation causes
localization of the active metal in larger pores with
15 better access to water; however, this does not preclude
use of both chelated and ion exchanged metal ions. The
intrazeolite paramagnetic complexes, as disclosed
herein, may be prepared by at least two different
methods, either by synthesizing the zeolite around a
20 complex or by diffusing the ligand into the zeolite to
form a complex. Chelation is also expected to function
as a second line of defense against any toxicity, as in
instances where a zeolite might be partially digested.

25 Not all molecular sieves exhibit ion exchange
properties, but several species do have this property,
including aluminosilicates, silicoaluminum phosphates and
metalloaluminum phosphates. Complexed paramagnetic ions
as herein disclosed are expected to be useful in
30 successfully encapsulating a paramagnetic species, and
thus expanding the range of zeolite-type compounds able
to enclose metal ions with little or no loss of the
paramagnetic material.

35 In certain applications, such as blood pool agents,
stability and stability may not be major concerns. In

-16-

such instances, chelates with a minimal number of ligands may be desirable in order to provide a maximal number of sites for water coordination. In general, the more accessible the paramagnetic ion is to bulk water, the more intense a signal measured. Where stability is important, multidentate ligands with a larger number of binding sites may be desired to assure retention of a toxic metal ion.

The following examples illustrate preferred embodiments of the practice of the invention. It should be understood that these examples are intended to be illustrative of the invention and in no way limiting.

EXAMPLE 1

Preparation of Zeolite-enclosed Trivalent Gadolinium

Calcium zeolite (calcium A), 10 g, was mixed with 2 g of $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ in approximately 100 ml deionized water and stirred at 30°C for 18 hr. The resulting zeolite suspension was suction filtered and washed extensively with deionized water until negative for chloride ion by silver nitrate test. The resulting CaGdA gave a negative test for free Gd^{3+} using the colorimetric indicator, xylenol orange. The zeolite was dried in a vacuum oven overnight at 50°C. The resulting sample contained 3.24% trivalent gadolinium by weight. Analogous procedures using NaA , NaX or NaY yielded the percent weight compositions shown in Table 1. MnCl_2 used in place of GdCl_3 formed MnNaX when exchanged into NaX .

-17-

TABLE 1

	Compound	Weight percent metal
5	GdNaA	6.18
	GdCaA	3.24
	GdNaX	6.19
	GdNaY	3.11
10	MnNaX	5.59

The various zeolites shown in Table 1 were suspended in EZ dispersant at the indicated weight percent. Image intensity data were recorded as shown in Table 2.

-18-

TABLE 2

	Compound	Intensity ¹	Std. Deviation	% sol'n*
5	GdNaY	1061.43	29.76	1
		382.19	12.42	0.1
		259.49	8.45	0.01
		228.97	8.55	0.001
		187.65	7.67	0.0001
10	GdNaX	454.08	19.91	1
		1273.13	36.84	0.1
		349.54	13.93	0.01
		219.17	10.84	0.001
		64.49	10.77	0.0001
15	GdNaA	365.06	12.51	1
		1522.71	29.67	0.1
		391.05	8.90	0.01
		237.03	9.37	0.001
		193.79	8.39	0.0001
20	GdCaA	408.25	47.06	1
		772.24	27.09	0.1
		280.11	10.38	0.01
		230.06	7.69	0.001
		200.32	8.56	0.0001
25	MnNaX	34.57	6.50	1
		1312.48	29.02	0.1
		453.10	16.17	0.01
		257.36	6.90	0.001
		185.37	8.66	0.0001
30				

¹

Mean value

*

All sample zeolites suspended in Ezpague
supernatant at the indicated wt %.

-19-

EXAMPLE 2Zeolite-Enclosed Complexes of Trivalent Gadolinium
Bis(8-hydroxyquinoline)chloro gadolinium(III)

5

13.5 g of aluminum isopropoxide was mixed with 4.8 g of sodium hydroxide and heated to 90°C for 0.5 hr before adding 18 ml of water with continued stirring. A silicate solution was prepared by combining 6 g silica, 4.8 g of NaOH and 18 ml of water in a teflon beaker. After the mixture had cooled to room temperature, the silicate and aluminate solutions were combined, followed by the addition of 50 ml of water. 0.18 g of bis(8-hydroxyquinoline)chlorogadolinium(III) was stirred into the gel over a period of 3 hr. The mixture was then heated at 90°C for 16 hrs in a sealed polypropylene bottle. After cooling to room temperature, the crystals were collected and washed with copious amounts of water. The zeolite crystals were then extracted with toluene for 24 hrs in a Soxhlet extractor to remove surface species. The crystals were suction filtered and dried at 100°C. The sample contained 0.5% gadolinium by weight.

Table 3 shows metal ion loading for the various zeolite-enclosed chelated trivalent gadolinium compositions, the imaging intensity and the weight percent solutions used for the measurements. The values are compared with water, air and the dispersant, EZpague.

30

-20-

TABLE 3

SUMMARY OF ZEOLITE PHANTOMS

	3 Gd 0.5 X-Gd-7 ¹ Mean SD	0.41 X-Gd-8 ² Mean SD	0.31 X-Gd-9 ³ Mean SD	0.29 A-Gd-5 ¹ Mean SD	0.38 A-Gd-6 ² Mean SD	0.40 A-Gd-7 ³ Mean SD
1‡	416.1	629.9	470.7	257.3	229.5	293.8
	24.8	36.4	37.2	25.9	13.1	11.0
0.1‡	204.3	318.7	208.0	199.7	212.0	221.3
	7.2	15.8	10.7	9.5	13.8	20.2
0.01‡	171.8	176.5	163.3	169.5	164.5	172.1
	6.5	7.9	5.6	6.3	7.0	6.1
0.001‡	163.6	159.7	156.5	158.1	163.8	167.5
	4.9	5.6	7.0	5.9	7.9	6.5
0.0001‡	159.9	152.3	149.	150.1	157.6	162.0
	6.2	5.9	6.8	7.5	6.7	8.1

1 8-hydroxyquinoline

2 DPA

3 phthalic acid

Air

Water

EZ-PAQUE

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

4.26	131.8	165.4
1.5	5.4	6.1

25

-21-

EXAMPLE 3

5 In Situ Formation of Zeolite-enclosed Trivalent
Gadolinium Complexes
Sodium X-type Zeolite Complexes

NaX zeolite was ion exchanged with $GdCl_3$, followed by exhaustive washing with water, overnight calcination at
10 350°C and reaction with 8-hydroxyquinoline. 2.0 g of Gd^{3+} -exchanged NaX was slurried for 24 hrs in 100 ml of ethanol containing 1.0 g of 8-hydroxyquinoline. The zeolite was filtered, washed with ethanol and extracted with toluene to remove surface complexes. The sample
15 contained 2.77% Gd by weight.

MFI Type Molecular Sieve Containing Trivalent Gadolinium

2 g of silica was dissolved in 3.5 ml of 48% by
20 weight hydrofluoric acid in a teflon beaker. 3 ml water containing 0.19 g of NaOH was added and the mixture allowed to cool to room temperature. 0.2 g of gadolinium trichloride was added (Si/Gd=61) followed by 1.46 g of tetrapropylammonium bromide, 14.3 ml of ammonium
25 hydroxide and an additional 25 ml of water. The gel was aged for 4 hrs, then autoclaved at 150°C for 24 hrs. After cooling to room temperature, the molecular sieve crystals were washed with water and dried at 90°C.

30 Table 4 shows the intensity of several different weight percents of gadolinium in type X zeolites after treatment of gadolinium (III) exchanged zeolite with 8-hydroxyquinoline.

35

-22-

TABLE 4

Compound	Intensity ¹	Standard Deviation	% ²
8HQGdx ³	954.98	36.4	1
	1,380.36	50.0	0.1
	431.68	17.1	0.01
	239.29	10.0	0.001
EZpague	206.59	9.6	
Water	186.51	7.1	
Air	7.78	4.2	

¹ Mean value² Samples suspended in EZpague at indicated wt%³ Gd³⁺ enclosed in type X zeolite treated with 8-hydroxyquinoline. Gd³⁺ is 3% by weight.EXAMPLE 4Gastrointestinal Imaging in the Rabbit

1 g of CaGdA was suspended in 99 ml dispersing medium prepared from E-Zpague[®] supernatant obtained by centrifugation of the BaSO₄. Approximately 200-300 cc was introduced into the stomach of a rabbit using a pediatric nasogastric (NG) tube at 12 hr and 4 hr prior to MRI. MRI scans were obtained periodically using a conventional T₁ weighed sequence. Figure 1 is an MRI scan 4 hr after the last administration. CaGdA was detected in the stomach, as indicated by the bright region in Panel A. 12 hr after administration the majority of the CaGdA had passed into the intestine and, as shown in Panel B, was concentrated in the jejunum region.

-23-

EXAMPLE 5Gastrointestinal Imaging in the Dog

5 Experimental protocol as described in Example 2 was followed in imaging the gastrointestinal tract of a dog, except that approximately 500 cc of 1% suspension of CaGdA was administered via NG tube. Figure 2A is an MRI scan taken 1 hour after administration. Figure 2B is an
10 MRI scan taken 3 hours after administration.

PROPHETIC EXAMPLE 6

The present example outlines the procedure
15 contemplated by the Applicants to be useful for the successful imaging of fistulas.

MRI Fistulagrams

20 A human patient will have been diagnosed as having a fistula. Generally, indications of infection should not be present as injection of fluid into the fistula might cause delocalization of an infection. In appropriate cases, the fistula will be injected with a suspension of
25 1% GdNaX in a suitable vehicle such as EZpaque supernatant. 5-15 cc injections will be used, depending on the size of the fistula. Imaging will then be performed using standard MRI procedures in order to visualize extent and location of fistulous tracts.

30

PROPHETIC EXAMPLE 7

The present example outlines the procedure
35 contemplated by the Applicants to be useful for the successful imaging of the gastrointestinal tract in pediatric practice.

-24-

MRI Imaging in Pediatric Patients

Young patients generally do not tolerate hyperosmotic iodinated agents currently in use. The following procedure would be used in this group of patients. The patient is administered 100-150 cc of a 1% solution of GdNaX in EZpaque supernatant or other suitable vehicle via a pediatric NG tube. The administered suspension must not be hyperosmolar. Images are obtained immediately after administration using standard MRI imaging procedures.

PROPHETIC EXAMPLE 8

The present example outlines the procedure contemplated by the Applicants to be useful for the successful imaging of surfaces to which prosthetic devices are to be fitted.

MRI of Amputated Human Long Limb Members

The limb to which a prosthetic device is to be fitted is prepared for attachment of a prosthetic device by surgical procedures as medically indicated to provide a suitable attachment surface. The surface is then coated with a material such as benzoin that will facilitate adherence of an applied powder to the surface. Zeolite-enclosed gadolinium, prepared as described in Example 1, is sufficiently to allow easy dispersion in a liquid or as an aerosol, washed extensively in water until the wash is free of gadolinium as determined by testing with xylenol orange, and then applied to the skin surface. Application is with an aerosol, either as a dry powder or as a suspension in a suspending agent such as alcohol or water. After the surface is coated with a fine layer of powder, images are obtained by standard

-25-

magnetic imaging procedures. The resulting images are used to design custom matings for the artificial limb.

5

The present invention has been described in terms of particular embodiments found by the inventors to comprise preferred modes of practice of the invention. It will be appreciated by those of skill in the art that in light of the present disclosure numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, any of a number of zeolites or molecular sieves could be used as the enclosing matrix and any of a number of cationic species could be present within the zeolite, some of which could be used to modify effects of the enclosed ion of interest, for example, trivalent gadolinium in imaging studies. These and obvious related modifications are contemplated to be within the scope of the claims.

REFERENCES

The references listed below are incorporated herein by reference to the extent they supplement, explain, provide a background for or teach methodology, techniques and/or compositions employed herein.

Lönnemark, M., Hemmingsson, A., Bach-Gansmo, T., Ericsson, A., Öksendal, A. Nyman, R. and Moxnes, A., Acta Radiol. 30, 193-196 (1989).

Hahn, P.F., Staark, D.D., Lewis, J.M., Saini, S., Elizondo, G., Weissleder, R., Fretz, C.J. and Ferrucci, J.T., Radiology 175, 695-700 (1990).

-26-

Claussen, Von C., Kornmesser, W., Laniado, M., Kaminsky, S., Hamm, B. and Felix, R., ROFO 148, 683-689 (1989).

Braybrook, H.H. and Hall, L.D., Drug. Des. Deliv. 4, 93-
5 95 (1989).

Breck, D.W., Zeolite Molecular Sieves, Krieger Publishing Company, Malabar, FL, 1984.

10 Rankel, L.A. and Valyocak, E.W., U.S. Patent No.
4,388,285, June 14, 1983.

Messina, C.A., Lok, B.M. and Flanigen, E.M., U.S. Patent
No. 4,544,143 (1985).

15 Wilson, S.T. and Flanigen, E.M., U.S. Patent No.
4,567,028 (1986).

-27-

CLAIMS:

1. An imaging method comprising administering to a mammal an amount of molecular sieve-enclosed paramagnetic ion, said amount being effective as a contrast or image-brightening agent.
2. An imaging method comprising administering a framework-modified molecular sieve to a mammal in an amount effective as a contrast or image-brightening agent wherein the framework is modified to include a paramagnetic ion.
3. The method of claim 1 or claim 2 wherein the paramagnetic ion comprises a rare earth or transition metal element.
4. The method of claim 1 or claim 2 wherein the paramagnetic ion comprises V^{+4} , Cu^{+2} , V^{+3} , Ni^{+2} , Cr^{+3} , Co^{+2} , Fe^{+2} , Co^{+3} , Mn^{+2} , Gd^{+3} , Dy^{+3} or Fe^{+3} .
5. The method of claim 1 wherein the molecular sieve-enclosed paramagnetic ion comprises a free ion or a complexed ion.
6. The method of claim 5 wherein the complexed ion is formed from a multidentate ligand.
7. The method of claim 5 wherein the complexed ion comprises a nitroxide functional group.

8. The method of claim 1 wherein the molecular sieve is characterized as having ion exchange properties sufficient to facilitate preferential binding of the paramagnetic ion.

5

9. The method of claim 1 or claim 2 wherein the molecular sieve comprises faujasite (FAU), Linde type A (LTA) or ZSM-5 type (MFI) zeolite.

10

10. The method of claim 1 or claim 2 wherein the molecular sieve comprises mordenite (MOR) type zeolite.

15

11. The method of claim 1 wherein the molecular sieve enclosed paramagnetic ion is administered anally, vaginally or by direct injection into a fistulous region.

20

12. The method of claim 1 wherein the molecular sieve enclosed paramagnetic ion is administered enterically or intravascularly.

25

13. The method of claim 1 wherein the molecular sieve enclosed paramagnetic ion is administered orally.

30

14. The method of claim 1 or claim 2 wherein the contrast or image-brightening agent is detected by magnetic resonance.

35

15. A method for gastrointestinal tract imaging comprising orally administering a pharmaceutically

-29-

acceptable molecular sieve-enclosed trivalent gadolinium formulation and detecting the gadolinium by magnetic resonance imaging.

5

16. The method of claim 15 wherein the molecular sieve-enclosed trivalent gadolinium is CaGdA or NaGdX .

10

17. The method of claim 15 wherein the trivalent gadolinium is chelated.

15

18. A method for gastrointestinal tract imaging comprising orally administering a pharmaceutically acceptable formulation comprising molecular sieve enclosed divalent manganese and detecting the manganese by magnetic resonance imaging.

20

19. The method of claim 18 wherein the molecular sieve-enclosed divalent manganese is CaMnA or NaMnX .

25

20. The method of claim 18 wherein the manganese is chelated.

30

21. A pharmaceutical composition useful as a contrast or image brightening agent for administration to mammals, said composition comprising a molecular sieve-enclosed paramagnetic ion in a pharmaceutically acceptable carrier.

35

22. The pharmaceutical composition of claim 21 wherein

-30-

the paramagnetic ion is chelated.

23. The pharmaceutical composition of claim 22 wherein
5 chelation is with hydroxyquinoline, phthalic acid or
dipicolinic acid.

24. The pharmaceutical composition of claim 22 wherein
the molecular sieve-enclosed paramagnetic ion is a
10 transition metal ion.

25. The pharmaceutical composition of claim 22 wherein
the paramagnetic ion comprises trivalent gadolinium.
15

26. The pharmaceutical composition of claim 22 wherein
the paramagnetic ion comprises Mn^{2+} .

27. The pharmaceutical composition of claim 22 wherein
the pharmaceutically acceptable carrier is a suspending
20 liquid, powder, or absorbing matrix.

28. The pharmaceutical composition of claim 22 further
comprising an amount of a second ion sufficient to alter
or attenuate pharmacological effects of said molecular
25 sieve-enclosed paramagnetic ion.

29. The pharmaceutical composition of claim 28 wherein
the second ion is a metal ion or a metal ion complex.
30

30. The composition of claim 28 wherein the second metal
35

-31-

ion is Na^{+1} or Ca^{+2} .

31. The composition of claim 28 wherein the second ion
5 is a nonmetal cationic species.

32. The composition of claim 28 wherein the second ion
is H^{+} , NH_4^{+} or R_4N^{+} wherein R is an alkyl group or hydrogen
10 selected in combination to prepare a cationic species
enclosable by the molecular sieve.

33. A zeolite composition comprising a chelated metal
15 ion and a free metal ion exchangeable with a
countervailing zeolite cation.

34. The zeolite composition of claim 33 wherein the
20 chelated metal ion and the metal ion are different.

35. The zeolite composition of claim 34 wherein the
chelated metal ion is complexed with a chelator having 2-
25 4 coordination sites.

36. The zeolite composition of claim 35 wherein the
chelator comprises 8-hydroxyquinoline, dipiconilic acid
30 or phthalic acid.

37. The zeolite composition of claim 35 wherein the
chelator comprises salicylamide, salicylic acid,
35 anthranilic acid, bipyridine, terpyridine,
phneantrroline, ethylenediamine,

-32-

bis(salicylaldehyde)ethylenediamine or ethylenediamine diacetic acid.

- 5 38. The zeolite composition of claim 33 wherein the metal ion is a paramagnetic ion exchangeable with a countervailing zeolite cation.
- 10 39. The zeolite composition of claim 33 useful as a contrast or image-brightening agent.

1/3



Fig. 1A



Fig. 1B

2/3




Fig. 2A



Fig. 2B

3/3



Fig. 2C



Fig. 2D

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 91/09222

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 49/00														
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: none; padding: 2px;">Int.Cl.5</div> </td> <td style="width: 75%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: none; padding: 2px;">A 61 K</div> </td> </tr> </table> <div style="text-align: center; font-size: small; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			<div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: none; padding: 2px;">Int.Cl.5</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: none; padding: 2px;">A 61 K</div>										
<div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: none; padding: 2px;">Int.Cl.5</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: none; padding: 2px;">A 61 K</div>													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border: none;"> <tr> <th style="width: 10%; border: none; text-align: left;">Category¹⁰</th> <th style="width: 60%; border: none; text-align: left;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; border: none; text-align: left;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="border: none; vertical-align: top;">X, Y</td> <td style="border: none; vertical-align: top;"> WO, A, 8911874 (L. HALL et al.) 14 December 1989, see page 3, paragraphs 1,2; page 5, paragraphs 3,4; page 6, paragraphs 1,2; page 2, paragraph 4 --- </td> <td style="border: none; vertical-align: top; text-align: center;">1-39</td> </tr> <tr> <td style="border: none; vertical-align: top;">Y</td> <td style="border: none; vertical-align: top;"> Medical Physics, vol. 11, no. 1, January-February 1984, (New York, US), M.A. BROWN et al.: "Transition metal-chelate complexes as relaxation modifiers in nuclear magnetic resonance", pages 67-72, see the whole article --- </td> <td style="border: none; vertical-align: top; text-align: center;">1-39</td> </tr> <tr> <td style="border: none; vertical-align: top;">X, Y</td> <td style="border: none; vertical-align: top;"> EP, A, 0186616 (SCHERING AG) 2 July 1986, see page 2, paragraph 3; example 12, page 13; example 14, page 14; claims 12,16 ----- </td> <td style="border: none; vertical-align: top; text-align: center;">1-39</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X, Y	WO, A, 8911874 (L. HALL et al.) 14 December 1989, see page 3, paragraphs 1,2; page 5, paragraphs 3,4; page 6, paragraphs 1,2; page 2, paragraph 4 ---	1-39	Y	Medical Physics, vol. 11, no. 1, January-February 1984, (New York, US), M.A. BROWN et al.: "Transition metal-chelate complexes as relaxation modifiers in nuclear magnetic resonance", pages 67-72, see the whole article ---	1-39	X, Y	EP, A, 0186616 (SCHERING AG) 2 July 1986, see page 2, paragraph 3; example 12, page 13; example 14, page 14; claims 12,16 -----	1-39
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X, Y	WO, A, 8911874 (L. HALL et al.) 14 December 1989, see page 3, paragraphs 1,2; page 5, paragraphs 3,4; page 6, paragraphs 1,2; page 2, paragraph 4 ---	1-39												
Y	Medical Physics, vol. 11, no. 1, January-February 1984, (New York, US), M.A. BROWN et al.: "Transition metal-chelate complexes as relaxation modifiers in nuclear magnetic resonance", pages 67-72, see the whole article ---	1-39												
X, Y	EP, A, 0186616 (SCHERING AG) 2 July 1986, see page 2, paragraph 3; example 12, page 13; example 14, page 14; claims 12,16 -----	1-39												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents :¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: none; padding: 2px; text-align: center;">03-04-1992</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: none; padding: 2px; text-align: center;">06 MAY 1992</div> </td> </tr> <tr> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: none; padding: 2px; text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: none; padding: 2px;"> </div> </td> </tr> </table>			<div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: none; padding: 2px; text-align: center;">03-04-1992</div>	<div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: none; padding: 2px; text-align: center;">06 MAY 1992</div>	<div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: none; padding: 2px; text-align: center;">EUROPEAN PATENT OFFICE</div>	<div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: none; padding: 2px;"> </div>								
<div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: none; padding: 2px; text-align: center;">03-04-1992</div>	<div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: none; padding: 2px; text-align: center;">06 MAY 1992</div>													
<div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: none; padding: 2px; text-align: center;">EUROPEAN PATENT OFFICE</div>	<div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: none; padding: 2px;"> </div>													

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9109222
SA 55207

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 28/04/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8911874	14-12-89	AU-A- 3767089	05-01-90
EP-A- 0186616	02-07-86	DE-A- 3443251	28-05-86
		DE-A- 3443252	28-05-86
		DE-A- 3508000	04-09-86
		AU-B- 583070	20-04-89
		AU-A- 5022585	29-05-86
		CA-A- 1252950	18-04-89
		JP-A- 61171434	02-08-86